I think Casper buys out trademarks for very old drugs. For the case of allopurinol, this website shows how trademark has changed hands over years.

Any idea why Suven Pharma is grinding down inspite of good qtrly results?

Promoter has sold off his banjara hill property & has given hefty interim dividend recently . He is now nearly 71. how Is 2nd gen,daughters mostly US citizen , ? are they interested in running the business ?

can the co be sold off & price is being brought down?

What caught attention in the press release (link) was mention that out of three applications, one is NDA (novel drug) approval:

Pre-Approval Inspections covering of three applications: NDA 016084, ANDA 217020, &
ANDA 217030.

Reading through the HSS ciruclar (available in public domain) carefully, this is an amendment to own existing NDA for 100 MG and 300 MG tablet for which approval was received prior to 1982 and listed as RLD drug. Over time, ALLOPURINOL has gathered competition with 25+ ANDA approval.

Mylan has NDA for Injectable route since 1996, however did not caught much competitor (except Gland and Hikma). My conjecture, Rx tablet are preferred by payers since facility cost may be involved with administrating injection through nurses/professionals.

Also, looked at the Orange book and was surprised (in mixed ways), all the filings under Casper are NDA only with RLD ‘Yes’. Most of them are bit legacy though (approved prior to 1982) with moderate competition only.

Thanks,
Tarun

A session worth watching @ Webinar with MD of GMM Pfaudler, on ‘How has GMM successfully used Acquisitions to create value’

Mr. Tarak Patel looks super confident as always… stock is technically trying for a breakout too…

At Price to Sales of 15x and EV/EBITDA of 293, no matter the growth and management quality (both look good) it should take some time to make money in this stock. Trent is equally expensive (given the current business size and business dynamics) and we shouldn’t look for high returns there either.

In both cases, the risk seems higher than the reward and Nykaa is even riskier given that business model is still evolving and the market cap is already that of an established giant.

Disclosure- Tracking position in Nykaa for learning perspective, no position in Trent.